Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-10-24
1999-04-06
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
558390, 546298, 549 80, C07C25508, C07C25532, A61K 3118
Patent
active
058919171
ABSTRACT:
The present invention relates to molecules capable of modulating tyrosine signal transduction to prevent and treat cell proliferative disorders or cell differentiation disorders associated with particular tyrosine kinases by inhibiting one or more abnormal tyrosine kinase activities.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
Aaronson, S.A. (1991). Growth factors and cancer Science 254, 1146-1153.
Arvidsson, A.-K., et al. (1994). Tyr-716 in the platelet-derived growth factor b-receptor kinase insert is involved in GRB2 binding and ras activation. Molecular and Cellular Biology 14, 6715-6726.
Baserga, R. (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research 55, 249-252.
Bisbee, C. (1995). Scatter factor/hepatocyte growth factor gene deletion leads to death in knockout mice. BioWorld Today 24 Feb. 1995, 2.
Carraway, L. K., et al. (1994). Ther erbB3 Gene Product Is a Receptor for Heregulin. The Journal of Biological Chemistry 269, 14303-14306.
Carraway, K. L., and Cantley, L. C. (1994). A Neu Acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78, 5-8.
Claesson-Welsh, L. (1994). Signal transduction by the PDGF receptors. Progress in Growth Factor Research 5, 37-54.
Cullen, K. J., Yee, D., and Rosen, N. (1991). Insulinlike Growth Factors in Human Malignancy. Cancer Investigation 9,443-454.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Inhibition of c-erB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5, 1001-1006.
Decker, T., and Lohmann-Matthes, M.-L. (1988). A quick and simple method for quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. of Imm. Methods 15, 61-69.
de Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., and Williams, L.T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
Dougall, W.C., Qian, X., Peterson, N.C., Miller, M. J., Samanta, A., and Greene, M. I. (1994). The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9,2109-2123.
Fendly, B.M. (1990). Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2
eu gene product. Cancer Research 50, 1550-1558.
Ferrara, N., and .perp-right. enzel, W. J. (1989). Pituitary follicular cells secrete a novel hepair-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications 161, 851-858.
Fingl, E., and Woodbury, D.M. (1975). The Pharmacological Basis of Therapeutics Chapter I, 1-46.
Floege, J., Eng, E., Young, B. A., and Johnson, R. J. (1993). Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney International 43, S-47-S-54.
Folkman, J. (1971. Tumor Angiogenesis: therapeutic implications. The New England Journal of Medicine v. 285, 18 Nov. 1971, 1182-1186.
Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82, 4-6.
Folkman, J., and Shing, Y. (1992). Angiogenesis. The Journal of Biological Chemistry 267, 10931-10934.
Fry, M. J., Panayotou, G., Booker, G. W., and Waterfield, M.D. (1993). New insights into protein-tyrosine kinase receptor signaling complexes. Protein Science 2, 1785-1797.
Giordano, S., Di Renzo, M. F., Olivero, M., Mondino, A., Zhen, Z., Medico, E., and Comoglio, P.M. (1992). The c-met/HGF receptor in human tumours. European Journal of Cancer Prevention 1, 45-49.
Gottardis, M.M., Robinson, S.P., and Jordan, C.V. (1988). Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: A model to study the tumoristatic action of tamoxifen. J. Steriod Biochem. 30, 311-314.
Harris, J.R., Lippman, M. E., Veronesi, U., and Willett, W. (1992). Breast Cancer. New England Journal of Medicine 327, 319-328.
Honegger, A.M., et al. (1987). Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51, 199-209.
Houck, K. A., et al. (1992). Dual regulataion of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. The Journal of Biological Chemisstry 267, 26031-26037.
Hu, P., et al. (1992). Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derive Growth Factor Receptors. Molecular and Cellular Biology 12, 981-990.
Jellinek, D., Green, L. S., and Janjic, N. (1994). Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 33, 10450-10456.
Jucker, M., et al. (1994). The Met/Hepatocyte Growth Factor Receptor (HGFR) Gene is Ovexpressed in Some Cases of Human Leukemia and Lymphoma. Leukemia Research 18, 7-16.
Kashishian, A., Kazlauskas, A., and Cooper, J.A. (1992). Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and P13 kinase in vivo. The EMBO J 11, 1373-1382.
Kashishian, A., and Cooper, J. A. (1993). Phosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase Cg1. Molecular Biology of the Cell 4, 49-57.
Kazlauskas, A., et al. (1993). The 64-kDa protein that associates with the platelet-derived growth factor receptor b subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. Proc. Natl. Acad. Sci. USA 90, 6939-6942.
Kendall, R.L., and Thomas, K. A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. 90, 10705-10709.
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., and Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
Kinsella, J.L., Grant, D.S., Weeks, B. S., and Kleinman, H.K. (1992). Protein kinase C regulates endothelial cell tube formation on basement membrane matrix, matrigel. Experimental Cell Research 199, 56-62.
Klagsbrun, M., and Soker, S. (1993). VEGF/VPF: the angiogenesis factor found? Current Biology 3, 699-702.
Korzseniewski, C., and Callewaert, D.M. (1993). An enzyme-release assay for natural cytotoxicity. Journal of Immunological Methods 64, 313-320.
Skehan, P., et al. (1990). New Colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute 82, 1107-1112.
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W.J., Ullrich, A., and McGuire, W. L. (1987). Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene. Science 235, 177-182.
Slamon, D.J., et al. (1989). Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer. Science 244, 707-712.
Sliwkowski, M. X., et al. (1994). Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High affinity receptor for Heregulin. The Journal of Biological Chemistry 269, 14661-14665.
Soman, N. R., Correa, P., Ruiz, B. A., and Wogan, G.N. (1991). The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. Proc. Natl. Acad. Sci. USA 88, 4892-4896.
Stein, D., et al. (1994). The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with hER2 in breast cancer. EMBO 13, 1331-1340.
Suzuki, K., et al. (1994). Expression of the c-met protoonocogene in human hepatocellular carcinoma. Hepatology, 1231-1236.
Takano, S. Gately, S., Jiang, J. B., and Brem, S. (1993). Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C. Mol. Bio. of the Cell 4, 358A.
Twamley-Stein, G., et al. (1993). The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 90, 7696-7700
McMahon Gerald
Nematalla Asaad S.
Sun Li
Tang Peng Cho
Rotman Alan L.
Sugen Inc.
LandOfFree
Certain acrylonitrile-sulfonamide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Certain acrylonitrile-sulfonamide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain acrylonitrile-sulfonamide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371810